Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $69.18.

A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Thursday, October 24th. Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $72.00 to $38.00 in a report on Monday, November 11th. Barclays cut their price objective on shares of Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a research note on Friday, August 9th. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price target on the stock.

Immunocore Stock Down 3.2 %

NASDAQ IMCR traded down $1.03 on Friday, hitting $31.59. The stock had a trading volume of 394,159 shares, compared to its average volume of 520,258. The business's fifty day moving average price is $32.44 and its 200 day moving average price is $38.52. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -33.25 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company's revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. Equities research analysts anticipate that Immunocore will post -0.96 earnings per share for the current year.

Institutional Trading of Immunocore

Several large investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its stake in shares of Immunocore by 1,867.3% in the 2nd quarter. SG Americas Securities LLC now owns 160,358 shares of the company's stock worth $5,435,000 after acquiring an additional 152,207 shares during the last quarter. Candriam S.C.A. raised its stake in Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company's stock worth $10,621,000 after purchasing an additional 124,417 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Immunocore in the 2nd quarter valued at approximately $3,686,000. Janus Henderson Group PLC grew its stake in shares of Immunocore by 45.8% in the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company's stock valued at $16,711,000 after buying an additional 80,748 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Immunocore by 16.2% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company's stock worth $13,470,000 after buying an additional 55,463 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.